Comparison of full-dose gemcitabine/cisplatin, dose-reduced gemcitabine/cisplatin, and gemcitabine/carboplatin in real-world patients with advanced urothelial carcinoma

Comparison of full-dose gemcitabine/cisplatin, dose-reduced gemcitabine/cisplatin, and gemcitabine/carboplatin in real-world patients with advanced urothelial carcinoma

Abstract Background While gemcitabine/cisplatin (GC) is the gold standard regimen for patients with advanced urothelial carcinoma (aUC), either dose-reduced GC or gemcitabine/carboplatin (GCa) is an alternative option for “cisplatin-unfit” patients. However, few studies have compared outcomes with t...

Full description

Bibliographic Details
Main Authors: Kazuma Sugimoto, Satoru Taguchi, Kenjiro Kishitani, Taketo Kawai, Kazuki Masuda, Yu Nakamura, Manami Kinjo, Mitsuhiro Tambo, Jimpei Miyakawa, Yoshiyuki Akiyama, Yuta Yamada, Yusuke Sato, Daisuke Yamada, Tohru Nakagawa, Hiroshi Fukuhara, Haruki Kume
Format: Article
Language:English
Published: BMC 2022-11-01
Series:BMC Urology
Subjects:
Advanced
Carboplatin
Cisplatin
Metastatic
Renal function
Urothelial carcinoma
Online Access:https://doi.org/10.1186/s12894-022-01139-9

Internet

https://doi.org/10.1186/s12894-022-01139-9

Similar Items